Crucell Terug naar discussie overzicht

Sanofi, Sanofi en nog eens Sanofi

1. wilb52 28 mei 2009 16:36

   auteur info

   • wilb52

     Lid sinds: 01 jan 2000

     Laatste bezoek: 08 jul 2022

   • Aanbevelingen

     Ontvangen: 1701

     Gegeven: 224

   •    Aantal posts: 5.104

   quote:

   Mr sponge schreef:

   Toch is het raar dat bijna de hele vaccinwereld geld krijgt voor het ontwikkelen van een vaccin. Dit terwijl de antibody's van Crucell al getest worden en waarschijnlijk ook werken. Waarom krijgt Crucell geen geld uit de USA? En waarom niet van de Nederlandse staat? De Nederlandse regering gingen toch inzetten op innovatie.... Maar nee hoor, ze gaan een vaccin bestellen dat nog ontwikkeld moet worden.
   
   [quote=aossa]
   "The CDC has approved two H1N1 seed strains, one produced via the classical egg based culturing method and another made using a patented reverse genetics method developed by Maryland-based MedImmune for its inhaled influenza vaccine FluMist."
   
   Ahumm...
   www.iex.nl/forum/topic.asp?topic=1198...
   [/quote]
   

   DAT denkt de markt van deze PAREL van de Biotech
   En Microsoft van de Biotech DUS ook.
   
   Want anders zou die koers wel Upperdepupo gaan.
   
   NOT dus.
   
   QED
2. flosz 29 mei 2009 12:26

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 22 jun 2023

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Wednesday, May 20, 2009
   Notes from BIO: BIO, Meet Sanofi; Sanofi, Meet BIO
   Sanofi-Aventis, which now calls itself a US and European company, is searching aggressively for partners, according to remarks made at a press conference on Tuesday.
   
   “The message we want to pass on at this BIO conference is we are partnering more and we wish to do more,” said Jean-Claude Muller. Muller is VP for R&D, prospective and strategic initiatives in CEO Chris Viehbacher’s plan to grow the proportion of Sanofi’s business that comes from external relationships - currently at 27 percent. The announcement was a first for Sanofi at BIO.
   
   “Our key message is the proportion [of business] will grow through partnering because value comes from partnerships,” Muller said. With a partnering word cloud like this (see pic) it's hard to argue isn't it?
   
   Muller and Philippe Goupit, who is VP for business development and corporate license, are charged by Viehbacher with reshaping the company’s R&D to make Sanofi a diversified global leader in health care. Viehbacher “is really turning the page and entering into the 21st century,” said Goupit, who also testified the CEO has pledged to spend 20 percent of his time on personally exploring new business opportunities. --Shirley Haley
   invivoblog.blogspot.com/2009/05/notes...
   
3. flosz 5 juni 2009 08:37

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 22 jun 2023

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   • JUNE 4, 2009
   Merck Assets Go on Block
   Sale of Animal-Health Lines Aims to Skirt Antitrust Issue
   
   By JEANNE WHALEN and DANA CIMILLUCA
   U.S. pharmaceutical company Merck & Co. has started contacting potential buyers for parts of its animal-health business as it determines what to sell after its planned $41 billion acquisition of Schering-Plough Corp., according to people familiar with the matter.
   In recent days, Merck has circulated information on two assets: its 50% stake in the Merial joint venture, which could be valued at roughly $5 billion, and Schering-Plough's animal-health business, called Intervet Schering-Plough Animal Health, which could fetch $6 billion to $8 billion, the people said.
   Merck plans to sell one of these assets in part to avoid any concerns from antitrust regulators that an acquisition of Schering-Plough would make it too dominant in the animal-medication business. Possible buyers of one of the businesses include Sanofi-Aventis SA, Novartis AG, Bayer AG, Eli Lilly & Co. and Boehringer Ingelheim GmbH, according to people familiar with the matter. Merck will decide which of the businesses to sell based on the levels of interest they generate.
   Merck spokeswoman Amy Rose confirmed that the company is exploring the possibility of selling one of the businesses, but said no decisions have yet been made. Ms. Rose said Merck considers animal health a "strong and valuable" business, and that the company plans to keep a foothold in it. Ms. Rose declined to comment on whether regulatory authorities have told Merck it needs to sell one of the businesses.
   
   Sanofi, which owns the other half of the Merial joint venture, is seen as the most likely buyer of Merck's 50% stake should Merck decide to sell it. Sanofi's chief executive, Christopher Viehbacher, has said in recent months that the company is interested in boosting its business in animal health. A Sanofi spokesman declined to comment further.
   
   Officials at Schering-Plough, Novartis, Bayer, Lilly and Boehringer Ingelheim declined to comment. In March, Lilly's chief executive expressed a desire to expand in animal health.
   Merial had total sales last year of more than $2.6 billion from products including Frontline flea and tick treatments for dogs and Ivomec, a medication that kills parasites in livestock. Intervet sells a variety of vaccines and medicines for pets and farm animals, and had sales of $3 billion last year, according to Schering-Plough.
   Drug companies see animal medications as attractive because they are subject to far less competition from cheap generics than human pharmaceuticals.
   The terms of the Merial joint venture say that neither Merck nor Sanofi can own animal-health assets outside of the venture, people familiar with the matter said. According to those terms, Merck wouldn't be able to remain in the joint venture and hold Intervet separately.
   online.wsj.com/article/SB124405109707...
   *****************
   Merial & Crucell:
   Crucell and Merial Announce Commercial License Agreement for PER.C6® Technology for Foot-and-Mouth Disease Vaccines
   
   Collaboration with USDA Agricultural Research Center Aims to Produce Vaccines for Rapid Control of FMD Outbreaks
   
   October 18, 2004
   Leiden, The Netherlands / Duluth, GA, USA - October 18, 2004 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and Merial, a world-leading animal health company, today announced that they have entered into a license agreement for the utilization of Crucell's PER.C6® technology for the development and commercialization of vaccines for foot-and-mouth disease (FMD). FMD is a highly communicable disease of production animals and is identified by the U.S. government as a potential bio-terrorism risk.
   Under the terms of the agreement, Crucell will receive an upfront payment, milestone payments, annual maintenance fees, and royalties on sales of vaccines. Further financial details were not disclosed.
   In on-going and close collaboration with the U.S. Department of Agriculture, Agricultural Research Service (ARS) Plum Island Animal Disease Center, Merial will further develop FMD vaccines discovered by ARS. These vaccines would be held in reserve for rapid distribution in the event of an accidental or terrorist-caused FMD outbreak.
   Dr. Robert Nordgren, Head of Biologics Research and Development at Merial, said "We are particularly proud to work with Crucell and the United States Department of Agriculture in the development of vaccines that not only enhance animal health, but also improve our country's level of bio-security, and its ability to respond quickly to threats to the agricultural industry. It now becomes essential that we move with speed through this final development process, since possible FMD outbreaks can occur unexpectedly."
   Dr. Luis L. Rodriquez, of ARS Plum Island, is Research Leader for the project. "Few effective intervention tools are available today to control FMD outbreaks," he said. "We have long needed an effective alternative to the culling and slaughter of all animals in infected and neighboring premises, which has previously been our only way of dealing with outbreaks. The combination of vaccine and antivirals is a very promising intervention tool for rapidly controlling and minimizing the impact of FMD outbreaks in the United States."
   "We consider Merial's choice of PER.C6® as the cell substrate for vaccines against such an important concern as foot-and-mouth disease as further confirmation of the strength of PER.C6® technology for the production of both human and veterinary vaccines," said Jaap Goudsmit, Crucell's Chief Scientific Officer.
   _______________________
   Crucell Announces Second PER.C6® Licensing Agreement with Merial
   Leiden, The Netherlands, December 22, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a second PER.C6® research license agreement with Merial, a leading animal health company.
   
   The non-exclusive agreement allows Merial to use the PER.C6® cell line for the development of gene therapy in a specific field of companion animal medicine and includes an option for a commercial license agreement. The new agreement follows the October 2004 licensing deal which allows Merial to utilize PER.C6® for the development and commercialization of veterinary vaccines for foot-and-mouth disease.
   

   Bijlage:
4. [verwijderd] 5 juni 2009 10:47

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Dat heb je weer bijzonder mooi aan elkaar geknoopt Flosz!
   
   Je geeft ons zoveel feitelijke informatie dat ik soms zelfs een "management samenvatting" zou willen. ;- ) Hoe fout kun je zijn?
5. flosz 8 juni 2009 08:25

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 22 jun 2023

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   JUNE 5, 2009, 9:08 A.M. ET
   Brazil Panel Freezes Sanofi-Aventis Pharmaceuticals Deal
   SAO PAULO (Dow Jones)--The Brazilian Justice Ministry Anti-Trust Division, or Cade, announced Thursday night that it has frozen the acquisition of local generic drugs manufacturer Medley by French drug company Sanofi-Aventis (SNY).
   According to Cade, the temporary measure comes at the request of the Brazilian government's Consumer Affairs Division, or SDE, which has asked for more study of the potential consequences of the proposed merger.
   In April, Sanofi-Aventis announced plans to buy Medley for about EUR500 million.
   The companies will now continue to operate separately until Cade can conclude its study and reach a permanent ruling. Cade did not set a date for a final decision.
   online.wsj.com/article/BT-CO-20090605...
   ______________________
   
   Sanofi-Aventis SA (SAN FP): France’s biggest drugmaker said reports that its acquisition of Brazil’s Medley SA has been frozen are “false.”
   
   There is a possibility that “minor overlaps will have to be divested or returned to the sellers,” the company said. The shares fell 30 cents, or 0.7 percent, to 46.12 euros.
   www.bloomberg.com/apps/news?pid=20601...
   
6. flosz 8 juni 2009 16:45

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 22 jun 2023

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Sanofi buys German insulin plant from Pfizer
   
   PARIS (Dow Jones)--Sanofi-Aventis (SNY) said Monday that Sanofi-Aventis Deutschland GmbH has purchased from Pfizer (PFE) the Diabel manufacturing plant in Frankfurt-Hochst, Germany, one of the largest state-of-the-art insulin manufacturing plants in the world.
   Sanofi-Aventis is exercising its step-in right regarding a purchase contract signed between Pfizer and Mannkind in Mar. 2009.
   The scope of the acquisition includes buildings, equipment, machinery and some existing contracts.
   This acquisition is valued at EUR30 million.
   The closing of the transaction will occur in the coming weeks after the fulfillment of all necessary formalities.
   online.wsj.com/article/BT-CO-20090608...
   
   en.sanofi-aventis.com/binaries/200906...
   ********************
   Crucell en die andere insuline-specialist www.novonordisk.com/
   investors.crucell.com/C/132631/PR/200...
   
7. flosz 10 juni 2009 09:15

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 22 jun 2023

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   
   AGRIBUZZ
   
   by David Leyonhjelm
   Posted 10 JUN 2009 2:54 PM
   Pre-emptive divestments
   Pfizer Australia is offering to divest a number of veterinary vaccines to secure ACCC approval for the company’s acquisition of Wyeth. The ACCC is currently considering the takeover under S50 of the Trade Practices Act, which prohibits mergers and acquisitions that might substantially lessen competition.
   The US$68 billion acquisition is global in scope and all about human pharmaceuticals. However, in Australia the animal health divisions of Wyeth (Fort Dodge) and Pfizer have a combined market share in vaccines that exceeds 70 per cent.
   Rather than risk delay due to competition concerns, Pfizer has advised the ACCC that as part of the proposed deal it will divest a number of animal health products in Australia. No divestment offer has been made in relation to human products.
   Pfizer’s proposal is to quit the weaker of two brands where they directly compete. Thus it suggests divesting Pfizer’s dog and cat multivalent vaccines and cattle botulism vaccine, plus Fort Dodge’s pig mycoplasma and sheep and cattle clostridial vaccines. Fort Dodge has long held a much stronger position in the small animal vaccine sector, while Pfizer is stronger in sheep and cattle with its former CSL vaccines.
   Divestments will inevitably be required by regulators in other countries as well, so Pfizer would naturally prefer a tidy global deal. However, vaccines must generally be produced within Australia due to quarantine constraints. Unless the acquiring company picks up one of the production plants in the deal, it might be forced to engage Pfizer to make them.
   Among the potential purchasers are Merial and Intervet/Schering-Plough, themselves subject to a takeover assessment by the ACCC (although there are now doubts about whether they will merged). Intervet/Schering-Plough already has a range of small and large animal vaccines but with a relatively low market share. Merial is not directly involved in vaccines in Australia but has a huge interest internationally including a contract with the Australian Government to provide Foot and Mouth Disease vaccine.
   Other companies that might be interested include Elanco (Lilly’s animal health division), Novartis, Bayer, Boehringer Ingelheim and Virbac. All except Elanco produce vaccines in other parts of the world while Virbac also sells a range of small animal vaccines in Australia produced by Intervet/Schering-Plough.
   Both the companion animal and livestock vaccine sectors are highly competitive, providing market leverage that benefits the rest of the business. Who wants the divested products and who ends up with them will be of considerable interest throughout the animal health market.
   www.businessspectator.com.au/bs.nsf/A...
8. flosz 11 juni 2009 08:22

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 22 jun 2023

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Sanofi denies U.S. acquisition report
   
   Wed Jun 10, 2009 5:05pm EDT
   PARIS, June 10 (Reuters) - French pharmaceutical group Sanofi-Aventis (SASY.PA) on Wednesday denied it had presented a major U.S. acquisition plan to its board, following a report in the edition of Les Echos newspaper due to appear on Thursday.
   The report said major shareholders in the world's fourth largest pharmaceutical company had rejected the planned acquisition, judging it too risky. Les Echos did not say where it got its information.
   A Sanofi-Aventis spokesman said the company "formally denied" that a major acquisition project in the U.S. had been presented to the board.
   www.reuters.com/article/euMergersNews...
   
   Sanofi-Aventis : un projet de fusion stoppé par les grands actionnaires
   Le nouveau patron du groupe pharmaceutique, Chris Viehbacher, a récemment travaillé sur une énorme acquisition aux Etats-Unis. L'opération, sans doute hostile, aurait coûté plusieurs dizaines de milliards de dollars. Les grands actionnaires ont stoppé le projet, jugé trop risqué. ...
   www.lesechos.fr/info/sante/4874083-sa...
   

   Bijlage:
9. aossa 11 juni 2009 10:42

   auteur info

   • aossa

     Lid sinds: 23 mei 2003

     Laatste bezoek: 07 mei 2024

   • Aanbevelingen

     Ontvangen: 4033

     Gegeven: 3336

   •    Aantal posts: 17.590

   Wie gelooft die man nog ?
10. wilb52 11 juni 2009 11:14

    auteur info

    • wilb52

      Lid sinds: 01 jan 2000

      Laatste bezoek: 08 jul 2022

    • Aanbevelingen

      Ontvangen: 1701

      Gegeven: 224

    •    Aantal posts: 5.104

    Begint toch wel erg veel op de typetjes van Koot en De Bie te lijken.
    (:->D)
11. aossa 13 juni 2009 14:04

    auteur info

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 07 mei 2024

    • Aanbevelingen

      Ontvangen: 4033

      Gegeven: 3336

    •    Aantal posts: 17.590

    Volgens franse berichtgeving zouden de grote aandeelhouders Total en L'Oreal niet akkoord zijn met grote overnameprojecten van SA CEO Viehbacher.
    Een overnameproject alla AMGEN zou aldus in de prullenbak zijn beland.
    
    Eigenlijk zouden ze willen uitstappen uit het kapitaal van Sanofi. Ze geven derhalve de voorkeur aan 'korte termijn waarde creatie' van hun aandeel in SA. Werpt allicht een andere kijk op de exploten van Viehbacher.
12. aossa 16 juni 2009 16:01

    auteur info

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 07 mei 2024

    • Aanbevelingen

      Ontvangen: 4033

      Gegeven: 3336

    •    Aantal posts: 17.590

    Rumoer, Rumor, Rumeur ...
    
    biz.yahoo.com/cc/4/104694.html
13. flosz 16 juni 2009 16:11

    auteur info

    • flosz

      Lid sinds: 13 feb 2008

      Laatste bezoek: 22 jun 2023

    • Aanbevelingen

      Ontvangen: 5298

      Gegeven: 2795

    •    Aantal posts: 7.005

    • June 16, 2009, 9:10 AM ET
    Parlez vous ‘Deal’? Sanofi-Aventis’ Big Takeover Rumors
    
    By Michael Corkery
    Is there another mega pharma deal in the works? A recent report in the French business newspaper Les Echos is sparking speculation that Sanofi-Aventis is on the hunt. The newspaper recently said Sanofi’s new chief executive, Chris Viehbacher, was working on a big, possibly hostile takeover of a U.S. company that would have cost tens of billions of dollars.
    In the end, the deal was deemed too risky by Sanofi’s largest shareholders, which include Total SA and L’Oreal, according to the June 11 Les Echos report.
    Some obvious takeover targets include Bristol-Myers Squibb, because the two companies already have an existing partnership developing Plavix, the blood clot medication. Amgen is another possible takeover candidate, because the aging Sanofi could use the biotechnology company to replenish its development pipeline.
    European bankers say taking over a mammoth company such as Amgen which has a $51 billion market value, could jeopardize Sanofi’s investment-grade credit rating because the French company may need to borrow more money to pull off the deal. A successful bid would likely require a hefty premium, weighing down Sanofi’s balance sheet even further. Sanofi has a market value of $90 billion.
    Sanofi denied that it had been working on such a deal.
    A more likely scenario is that Sanofi would go after smaller prey, such as Allergan, which makes Botox and has a market value of $14.1 billion. Or, perhaps Biogen Idec, the drug maker where Carl Icahn has been successfully agitating for seats on the board. In the fall of 2007, Icahn prodded Biogen, which has a market value of $14.8 billion, to put itself on the block and Sanofi was mentioned as a potential bidder.
    Icahn may find a French suitor after all.
    blogs.wsj.com/deals/2009/06/16/par-le...
    
14. flosz 17 juni 2009 07:24

    auteur info

    • flosz

      Lid sinds: 13 feb 2008

      Laatste bezoek: 22 jun 2023

    • Aanbevelingen

      Ontvangen: 5298

      Gegeven: 2795

    •    Aantal posts: 7.005

    Sanofi-Aventis to Invest in Korea
    Multinational pharma giant Sanofi-Aventis will invest W50 billion in Korea's pharmaceutical research and development field over the next five years (US$1=W1,258).
    
    The world's fourth-largest pharmaceutical company has signed a memorandum of understanding with Seoul's Health Ministry to invest in the country's biotechnology industry by supporting clinical tests that seek to develop new drugs.
    
    Company publicity said the decision was based on Korea's outstanding human resources as well as its excellent performance in R&D.
    english.chosun.com/site/data/html_dir...
    **************
    Delphi Genetics grants licence to Sanofi Pasteur for antibiotic-free manufacturing of vaccines
    15 Jun 2009
    - Novel microbiological technique permits biosynthesis of proteins at higher yields and without reliance on antibiotics -
    Charleroi, Belgium, June, 15, 2009 - Delphi Genetics SA (“Delphi”) today announced that the company has entered into an agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, for the manufacture of biological pharmaceuticals using Delphi’s patented StabyExpressTM technology.
    StabyExpress is a new approach to stabilising the genetic machinery required to manufacture proteins, the raw materials at the heart of many modern biopharmaceuticals including vaccines, monoclonal antibodies and therapeutic proteins. Biopharmaceuticals represent a growing proportion of marketed drugs worldwide with 15 % of the worldwide pharmaceutical market.
    Delphi’s StabyExpress technology improves the efficiency of protein manufacture and at a higher quality than alternative approaches.
    Moreover, the technology avoids use of antibiotic resistance genes and is therefore in line with recent FDA and EMEA recommendations against the use of antibiotics in manufacturing of proteins for human and veterinary use. Many biological products currently in clinical development and licensed for sale rely on antibiotic resistance genes in the manufacturing process. The use of the StabyExpress avoids any concern regarding the use of antibiotic resistance and offers next generation biological products a more regulatory-consistent manufacturing strategy.
    StabyExpress is a proprietary technology developed by Delphi Genetics. Under the agreement Sanofi Pasteur will have the non-exclusive right to use the technology for a range of vaccines it is planning to manufacture. In exchange for the licence, Delphi will receive milestone payments and royalties. No further financial details of the agreement were disclosed.
    www.delphigenetics.com/news-78.html
    
    
15. [verwijderd] 17 juni 2009 10:36

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Jullie weten dat ik op biotechnologisch gebied een NONO ben. Hoe moet ik dit bericht interpreteren?
    
    Betekent dit dat Sanofi waarschijnlijk geen gebruik zal maken van PER.C6/Star voor eventuele antibody-programma's? Of is dat te kort door de bocht?
    
    

    quote:

    flosz schreef:

    Sanofi-Aventis to Invest in Korea
    Multinational pharma giant Sanofi-Aventis will invest W50 billion in Korea's pharmaceutical research and development field over the next five years (US$1=W1,258).
    
    The world's fourth-largest pharmaceutical company has signed a memorandum of understanding with Seoul's Health Ministry to invest in the country's biotechnology industry by supporting clinical tests that seek to develop new drugs.
    
    Company publicity said the decision was based on Korea's outstanding human resources as well as its excellent performance in R&D.
    english.chosun.com/site/data/html_dir...
    **************
    Delphi Genetics grants licence to Sanofi Pasteur for antibiotic-free manufacturing of vaccines
    15 Jun 2009
    - Novel microbiological technique permits biosynthesis of proteins at higher yields and without reliance on antibiotics -
    Charleroi, Belgium, June, 15, 2009 - Delphi Genetics SA (“Delphi”) today announced that the company has entered into an agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, for the manufacture of biological pharmaceuticals using Delphi’s patented StabyExpressTM technology.
    StabyExpress is a new approach to stabilising the genetic machinery required to manufacture proteins, the raw materials at the heart of many modern biopharmaceuticals including vaccines, monoclonal antibodies and therapeutic proteins. Biopharmaceuticals represent a growing proportion of marketed drugs worldwide with 15 % of the worldwide pharmaceutical market.
    Delphi’s StabyExpress technology improves the efficiency of protein manufacture and at a higher quality than alternative approaches.
    Moreover, the technology avoids use of antibiotic resistance genes and is therefore in line with recent FDA and EMEA recommendations against the use of antibiotics in manufacturing of proteins for human and veterinary use. Many biological products currently in clinical development and licensed for sale rely on antibiotic resistance genes in the manufacturing process. The use of the StabyExpress avoids any concern regarding the use of antibiotic resistance and offers next generation biological products a more regulatory-consistent manufacturing strategy.
    StabyExpress is a proprietary technology developed by Delphi Genetics. Under the agreement Sanofi Pasteur will have the non-exclusive right to use the technology for a range of vaccines it is planning to manufacture. In exchange for the licence, Delphi will receive milestone payments and royalties. No further financial details of the agreement were disclosed.
    www.delphigenetics.com/news-78.html
    
    

16. [verwijderd] 18 juni 2009 14:25

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Not Crucell
    
    Viehbacher said his policy toward purchases hasn’t changed. “You can look at large acquisitions but they’ve got to create value,” he said.
    
    Viehbacher said he remains committed to expanding Sanofi’s vaccine business, either through takeovers or internal growth.
    
    “We’ll look” at acquisitions, “but organic growth also is an opportunity” for the vaccine business, in particular thanks to its “strong footprint in Asia,” he said. Sanofi is targeting “double-digit” growth in vaccines sales in Asia, Viehbacher said.
    
    The Sanofi chief denied interest in buying Dutch vaccine maker Crucell NV, which was cited as a possible target earlier this year. Sanofi has partnerships with Leiden-based Crucell.
    
    “Crucell is no secret to us,” Viehbacher said. “In my view, if you can partner, why acquire?”
    
    www.bloomberg.com/apps/news?pid=20601...
17. [verwijderd] 18 juni 2009 14:28

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    gocrucellgo schreef:

    “Crucell is no secret to us,” Viehbacher said. “In my view, if you can partner, why acquire?”
    
    

    Natuurlijk, omdat ze een werelddeal met Crucell hebben gesloten (Influenza), hetgeen Brus ook steeds aangeeft.
    
    Dirk
18. flosz 18 juni 2009 14:53

    auteur info

    • flosz

      Lid sinds: 13 feb 2008

      Laatste bezoek: 22 jun 2023

    • Aanbevelingen

      Ontvangen: 5298

      Gegeven: 2795

    •    Aantal posts: 7.005

    quote:

    gocrucellgo schreef:

    “In my view, if you can partner, why acquire?”
    

    Funny fucker....pist weer naast het potje.
    www.youtube.com/watch?v=IM39yIKoSo4
19. [verwijderd] 18 juni 2009 15:03

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    gocrucellgo schreef:

    
    
    The Sanofi chief denied interest in buying Dutch vaccine maker Crucell NV, which was cited as a possible target earlier this year. Sanofi has partnerships with Leiden-based Crucell.
    
    “Crucell is no secret to us,” Viehbacher said. “In my view, if you can partner, why acquire?”
    
    

    ja,... ja... Viebachertje, we weten het nu wel.
    
    "A clever liar gives details, but the cleverest don't.
    
    :-)
    
    Dirk
20. aossa 19 juni 2009 18:57

    auteur info

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 07 mei 2024

    • Aanbevelingen

      Ontvangen: 4033

      Gegeven: 3336

    •    Aantal posts: 17.590

    Sanofi CEO Bets Outside U.S., Gears Up for Flu Pandemic, and Seeks To Learn From Biotech
    
    Luke Timmerman 6/19/09
    
    Not long ago, drug companies would break out quarterly income streams from the U.S., Europe, Japan, and something called ROW, as in rest-of-world. Investors usually didn’t care about the last numbers, because they were little more than a rounding error.
    
    That’s not the case anymore, as these countries are often called “emerging markets.” They’ve grown enough that Chris Viehbacher, CEO of one of the world’s largest drug companies, Paris-based Sanofi-Aventis (NYSE: SNY), traveled to Seattle this week to curry favor with global health officials at the Pacific Health Summit. The head of a major drug company might have gotten a cold shoulder at a meeting like this a decade ago, but these officials welcomed Viehbacher. Sanofi made headlines at the summit, as it said it plans to donate as many as 100 million doses of flu vaccine to the World Health Organization to help poor countries cope with the swine flu pandemic.
    
    This could all be written off as some kind of public relations exercise, but I wondered if there’s more to the story. The pharmaceutical industry is terrified by a series of patent expirations coming over the next few years, which will allow a flood of cheap generic copies to grab market share away from franchise products that generate an estimated $67 billion in annual sales. Not much has emerged in the industry’s R&D pipeline to replace all these aging blockbusters. Some analysts predict pharma companies will have to continue acquiring and partnering with innovative biotech companies to sustain themselves.
    
    Sanofi has made a couple aggressive moves like this since Viehbacher took over Sanofi in December. Earlier this year, it acquired cancer drugmaker BiPar Sciences for $500 million (giving BiPar investor Paul Allen a big payday), and partnering with South San Francisco-based cancer drug developer Exelixis for a deal possibly worth more than $1 billion.
    
    But Viehbacher also has his sights on making money on low profit-margin, high-volume products in parts of the world that are off the pharma industry’s beaten track. It’s part of a strategy to make Sanofi a more globally diversified company, rather than placing all its chips on the U.S. and Europe—where governments are looking for ways to trim healthcare spending.
    
    Here are edited highlights of a wide-ranging conversation we had about industry trends, the reasons for donating flu vaccine, and how he likes to deal with biotechs.
    
    Xconomy: Why come here to the Pacific Health Summit?
    
    Chris Viehbacher: I laid out a strategy for the company in February, to become a global healthcare company, versus a pharmaceutical company focused on the U.S. and Europe. That means we want to be present in all countries, and therefore, you have to address all diseases in all countries. You can’t just take medicines doing well in the U.S., and try to find people rich enough in other countries to buy them. So, the company is hugely committed to these huge global health issues. We probably, I think, do more than just about anybody. We are very significant in malaria. We are the only company doing things for Sleeping Sickness. We have a new antibiotic coming for tuberculosis, which could cut the treatment time down to four months [from six months], which is huge in the area of TB. We are spending huge amounts of money developing a Dengue Fever vaccine and developing facilities for it. We have partnered with a lot of people in that room, whether it’s the Gates Foundation, GAVI[Global Alliance for Vaccines and Immunization], the Global Fund to Fight AIDS, Tuberculosis, and Malaria. Those are all people we try to work with on a regular basis. It’s very much in line with our strategy. I take a personal interest in these global health issues, and it’s good to meet folks.
    
    X: To what extent does the donation of flu vaccine amplify the company’s global health effort, or show that you’re serious?
    
    CV: The pandemic flu donation is exceptional. I’d normally say donations are not the way to deal with issues of access to medicine. It’s not sustainable. If we were dealing with malaria, or tuberculosis, then I wouldn’t probably propose that. But a pandemic is a different kettle of fish. It’s in a concentrated time frame potentially. So you don’t have time to build a tiered pricing model and everything else. If we really get into a pandemic, there’s going to be a significant amount of competition—we’re already seeing it—for the first doses off the line. From the interest of public health, it would be a mistake to say all the richest countries get the vaccine. This would put [World Health Organization director general] Margaret Chan and the WHO into an untenable position. So, we felt we needed to respond to Margaret Chan’s call to action collectively to provide a stock of vaccine doses that she could deploy on a rapid basis where [the] need is, and to ensure an element of solidarity between all countries and all patients. It’s an exceptional set of circumstances with a pandemic, and that’s why we need exceptional measures, a donation in this case.
    
    X: How much is this costing the company, or hurting the bottom line?
    
    CV: I have to say, I have no idea. At this stage, we don’t even know what the dose is yet. We’re doing clinical trials, so we don’t know what the cost of an individual dose of the vaccine is going to be. But it’s not going to have a negative impact on earnings, because there is no normal market for pandemic flu. If we donate 100 million, we can produce 800 million over a year. There will still be some incremental profit for the company, coming out of pandemic flu vaccine. This just ensures that everybody gets an equitable opportunity to get the vaccine.
    
    X: So to clarify, you can make 800 million doses a year?
    
    CV: Roughly, assuming a 15-milligram dose. That’s the dose of the seasonal flu. What we actually don’t know is what the actual dose [for pandemic flu] vaccine will be. We just all assume it’s the same dose. It could be [different]. We will do clinical trials at 7.5 milligrams, 15 milligrams, and 30 milligrams. That’s all without an adjuvant [an immune-boosting compound], and an adjuvant could potentially reduce the dose further. We’ve just basically said we produce 220 million doses of normal seasonal flu vaccine every year, and that’s with three strains. You’d triple that, because a pandemic flu vaccine will be a monovalent [single-strain] vaccine. Then you have to take into account that we don’t actually produce that seasonal flu vaccine year-round on a 24/7 basis. That gets you from 660 million doses to 800 million on a rough basis.
    
    X: Are you confident this will work against H1N1?
    
    CV: That’s why we’re all busy working on manufacturing clinical trial lots so we can do clinical trials. They won’t necessarily give us efficacy, they’ll give us safety. But if you think about the fact that there’s been four types of H1N1 flu virus in the normal seasonal flu vaccine over the past few years, and although this is a different strain, you’d gain some confidence from being able to produce a seasonal flu vaccine using a strain like that. But of course, we won’t really be able to judge that until we start using it.
    
    X: How does TB fit into the bigger picture of your global health plan?
    
    CV: We have a historical interest because it was one of our former companies, that developed